European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 4 , Pages 397-404 , October 2007

Smoking Cessation Interventions in Clinical Practice

  • J. Cornuz

      Affiliations

    • Corresponding Author InformationCorresponding author. Dr. J. Cornuz, Department of ambulatory care and community medicine, Lausanne University Hospital, 44, Rue du Bugnon, CH–1011 Lausanne, Switzerland.

,Accepted 7 June 2007.

References 

  1. U.S. Department of health and human services . The Health Benefits of Smoking Cessation. A report of the Surgeon General. (DHHS Publication No.[CDC] 90-8416). Atlanta, GA: Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990;
  2. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328:1519
  3. Cornuz J. Treating tobacco use and dependence in clinical practice. Expert Opin Pharmacother. 2006;7:783–792
  4. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating Tobacco Use and Dependance: Clinical Practice Guideline (revised 2000). Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Dept of Health and Human Services; 2000;Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid = hstat2.chapter.7644
  5. Thorndike AN, Rigotti NA, Stafford RS, Singer DE. National patterns in the treatment of smokers by physicians. JAMA. 1998;279:604–608
  6. Raw M, Mcneill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax. 1998;53(Suppl. 5 Pt 1):S1–S19
  7. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506–512
  8. U.S. Department Of Health and Human Services . Reducing Tobacco Use: A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health promotion, Office on Smoking and Health; 2000;
  9. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ. 2000;321:355–358
  10. Cornuz J, Humair JP, Seematter L, Stoianov R, Van Melle G, Stalder H, et al. Efficacy of resident training in smoking cessation: a randomized, controlled trial of a program based on application of behavioral theory and practice with standardized patients. Ann Intern Med. 2002;136:429–437
  11. Kunze M. Maximizing help for dissonant smokers. Addiction. 2000;95(Suppl. 1):S13–S17
  12. Rosengren A, Wilhelmsen L, Wedel H. Coronary heart disease, cancer and mortality in male middle-aged light smokers. J Intern Med. 1992;231:357–362
  13. Fagerstrom KO. Can reduced smoking be a way for smokers not interested in quitting to actually quit?. Respiration. 2005;72:216–220
  14. Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet. 1987;2:27–30
  15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146
  16. Richmond RL, Kehoe L, De Almeida Neto AC. Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch. Heart. 1997;78:617–618
  17. Waring WS. The role of pharmacotherapy in assisting smoking cessation. Eur J Clin Pharmacol. 2003;59:351–356
  18. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18:297–308
  19. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. 1996;91:1293–1306
  20. Wallstrom M, Sand L, Nilsson F, Hirsch JM. The long-term effect of nicotine on the oral mucosa. Addiction. 1999;94:417–423
  21. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798
  22. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–1431
  23. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  24. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59:1007–1024
  25. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;CD000031
  26. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691
  27. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003;21:914–920
  28. Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals. Am J Health Behav. 2005;29:240–249
  29. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59:366–373
  30. Belson MG, Kelley TR. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med. 2002;23:223–230
  31. Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006;20:945–960
  32. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
  33. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571–1577
  34. Cinciripini P. Pooled analysis of three short-term randomised, double-blind, placebo, controlled trials with rimonabant 20 mg/d in smoking cessation. 8th European Conference of the Society for Research on Nicotine and Tobacco. Kusadasi-Ephesus, Turkey, 23–26 September, 2006.
  35. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35:2031–2040
  36. Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol. 1999;67:563–570
  37. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278:1759–1766
  38. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control. 2006;15:152–159

PII: S1078-5884(07)00411-X

doi: 10.1016/j.ejvs.2007.06.009

European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 4 , Pages 397-404 , October 2007

Article Tools